Outlive
LongevityResearchHub
Preliminary — 30/100 Other medRxiv

Testing Three Anti-Aging Drugs in Older Adults: A Clinical Trial Protocol

REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect. Rationale and protocol for a trial of biological effect.

medrxiv (preprint) Wilson, D.; Acharjee, A.; Duggal, N. A.; Hombrebueno, J. R.; Jones, S. W.; Lewis, J. W.; de Magalhaes, J. P.; Martinez-Serrato, Y. P.; Mazaheri, A.; McGettrick, H. M.; Mondal, S. M.; Naylor, A. J.; Nixon, A.; Nicholson, T.; Partridge, J.; Pinkney, T.; Rattray, N. J. W.; Steves, C.; Tomkova, K.; Welch, C.; Jackson, T.
TL;DR

This is a protocol paper describing an upcoming clinical trial that will test whether three drugs (metformin, fisetin, and spermidine) can reduce senescent cells and reverse aging hallmarks in healthy adults over 70 within three weeks. The study hasn't been completed yet, so no results are available—this paper outlines the research plan.

Credibility Assessment Preliminary — 30/100
Study Design
Rigor of the research methodology
6/20
Sample Size
Whether the study was sufficiently powered
7/20
Peer Review
Review status and journal reputation
3/20
Replication
Has this finding been independently reproduced?
4/20
Transparency
Funding disclosure and data availability
10/20
Overall
Sum of all five dimensions
30/100

What this means

This is a well-designed but early-stage clinical trial protocol testing whether three anti-aging drugs can reverse aging biology in older adults—no results yet. It's a promising step toward human evidence, but results (when they arrive) should be interpreted as preliminary proof-of-concept, not proof these drugs actually slow aging.

Red Flags: Preprint status (not yet peer-reviewed). No results reported—this is a protocol only. Small sample size (60 total, 20 per arm) limits statistical power. No mention of a placebo or control arm, compromising causal inference. Very short intervention period (3 weeks) may be too brief to detect meaningful hallmark reversal. Trial completion and publication date unknown; risk of publication bias if negative results are shelved.

The aging process involves progressive deterioration in the body's ability to handle stress—infections, surgery, or illness hit older adults harder. Scientists believe this reduced 'resilience' stems from fundamental biological aging mechanisms, collectively called the 'hallmarks of aging,' which include accumulation of senescent (zombie) cells, mitochondrial dysfunction, chronic inflammation, and epigenetic changes. Geroprotectors are drugs hypothesized to slow aging and extend healthy lifespan by targeting these mechanisms, but rigorous mechanistic studies in living human volunteers remain sparse.

The REPROGRAM trial is designed to fill this gap. Researchers will recruit 60 healthy volunteers aged 70+ (equal gender split) and randomly assign them to one of three treatments: metformin (a diabetes drug), fisetin (a plant flavonoid), or spermidine (a polyamine). Each participant will receive their assigned drug for three weeks. Before and after treatment, the team will collect blood, adipose tissue biopsies, and stool samples, then measure multiple aging hallmarks including senescent cell burden (via SA-β-GAL staining), autophagy, immune aging, inflammation markers, epigenetic age, and microbial diversity.

The primary endpoint is whether a three-week course reduces senescent cells in fat tissue. Secondary analyses will assess effects on other hallmarks of aging. All three drugs have reasonable safety records in older adults, and each has some evidence for anti-aging effects in laboratory or animal studies, making this a pragmatic 'best available candidates' approach. The trial is registered (ISRCTN47919839) and has ethical approval, which supports transparency.

Critical limitations are substantial. This is a protocol paper, not a results paper—the trial hasn't finished, so we have zero actual findings. The three-week intervention window is very short; meaningful reversal of aging hallmarks may require longer treatment. With only 20 participants per arm, the study is underpowered to detect modest effects, particularly for rare biomarker changes. No control/placebo arm is mentioned, which weakens causal inference. The sample is presumably from a single country/health system, limiting generalizability. Publication bias is a risk—negative results may be less likely to appear.

This work addresses a genuine gap: most geroprotector research occurs in cell cultures or animals, not in living humans. Testing multiple hallmarks simultaneously is scientifically sound. However, a three-week trial in 60 people is a 'proof of mechanism' study, not a definitive test of efficacy or safety at scale. Positive results would be interesting but preliminary; negative results wouldn't rule out longer-term benefit.

For longevity research, this trial matters because it could generate human biomarker data on whether widely-touted geroprotectors actually move the biological needle in real older adults—something largely unknown. If published (high-impact gerontology journals are promised), it will shift the field toward human mechanistic work. However, results should be interpreted cautiously as early-stage evidence, not as proof that these drugs slow aging in the real world.

Autophagy Epigenetics Metformin Regulatory Senolytics Stem Cells
View Original Source

0 Comments